Difference between revisions of "Epithelioid sarcoma"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://ascopubs.org/doi/abs/10.1200/" to "https://doi.org/10.1200/") |
m (→Chemotherapy) |
||
| Line 35: | Line 35: | ||
|} | |} | ||
''Note: this study has not yet been published, to our knowledge.'' | ''Note: this study has not yet been published, to our knowledge.'' | ||
| − | ==== | + | ====Targeted therapy==== |
*[[Tazemetostat (Tazverik)]] 800 mg PO twice per day | *[[Tazemetostat (Tazverik)]] 800 mg PO twice per day | ||
Revision as of 16:08, 27 August 2020
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
All lines of therapy
Tazemetostat monotherapy
| back to top |
Regimen
| FDA-recommended dose |
| Study | Years of enrollment | Evidence |
|---|---|---|
| Gounder et al. 2017 (EZH-202) | NR in abstract | Phase II (RT) |
Note: this study has not yet been published, to our knowledge.
Targeted therapy
- Tazemetostat (Tazverik) 800 mg PO twice per day
Continued indefinitely
References
- Abstract: Mrinal M. Gounder, Silvia Stacchiotti, Patrick Schöffski, Steven Attia, Antoine Italiano, Robin Jones, George D. Demetri, Stephen Blakemore, Alicia Clawson, Scott Daigle, Scott Ribich, Maria Roche, Jill Rodstrom, Peter T.C. Ho, and Gregory Michael Cote. Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950). Journal of Clinical Oncology 2017 35:15_suppl, 11058-11058. link to abstract CT.gov